Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2009 Feb;5(1):21-34.
Epub 2009 Mar 26.

Management of postoperative nausea and vomiting: focus on palonosetron

Neil A Muchatuta  1 , Michael J Paech
Affiliations

Management of postoperative nausea and vomiting: focus on palonosetron

Neil A Muchatuta et al. Ther Clin Risk Manag. 2009 Feb.

Abstract

Postoperative nausea and vomiting (PONV) remains a significant problem in modern anesthetic practice, with an incidence in high-risk groups of up to 80%. In addition to being unpleasant and distressing for the patient, PONV has the potential to adversely affect patient and surgical outcomes. Advances in PONV prophylaxis over recent years include using non-pharmacological means to reduce baseline risk, a change to less emetogenic anesthetic techniques and the combination of multiple antiemetic drugs. The 5-hydroxytryptamine-3 (5-HT(3)) antagonists have proven a particularly valuable addition to the armamentarium against PONV. Palonosetron is a second-generation 5-HT(3) antagonist that has recently been approved for prophylaxis against PONV. It has unique structural, pharmacological and clinical properties that distinguish it from other agents in its class. This review summarizes current evidence on PONV prophylaxis, reviews the 5-HT(3) antagonists in particular and focuses on the established and future roles of palonosetron.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Structures of palonosetron and other 5-HT3 antagonists. Reproduced with permission from Rojas C, Grunberg S, Rosti G. 2007. Creating real benefit for patients at risk of nausea and vomiting: palonosetron-from bench to bedside. Clin Adv Hematol Oncol, 5(12 Suppl 19):1–20. Copyright © 2007 Millenium Medical Publishing.
Figure 2
Figure 2
0- to 24-hour PONV: complete response (CR), no nausea and no emesis. *p< 0.017; **p < 0.05. Data derived from Kovac et al 2008 and Candiotti et al 2008. Abbreviations: Palo, palonosetron; PONV, postoperative nausea and vomiting.
Figure 3
Figure 3
24- to 72-hour PONV: complete response (CR) and no emesis. *p< 0.017. Data derived from Kovac et al 2008 and Candiotti et al 2008. Abbreviations: Palo, palonosetron; PONV, postoperative nausea and vomiting.
See this image and copyright information in PMC

References

    1. Macario A, Weinger M, Carney S, Kim A. Which clinical anesthesia outcomes are important to avoid? The perspective of patients. Anesth Analg. 1999;89(3):652–8. - PubMed
    1. Gan T, Sloan F, Dear Gde L, El-Moalem HE, Lubarsky DA. How much are patients willing to pay to avoid postoperative nausea and vomiting? Anesth Analg. 2001;92(2):393–400. - PubMed
    1. van den Bosch JE, Bonsel GJ, Moons KG, Kalkman CJ. Effect of postoperative experiences on willingness to pay to avoid postoperative pain, nausea, and vomiting. Anesthesiology. 2006;104(5):1033–9. - PubMed
    1. Lee A, Gin T, Lau AS, Ng FF. A comparison of patients’ and health care professionals’ preferences for symptoms during immediate postoperative recovery and the management of postoperative nausea and vomiting. Anesth Analg. 2005;100(1):87–93. - PubMed
    1. Myles PS, Williams DL, Hendrata M, Anderson H, Weeks AM. Patient satisfaction after anaesthesia and surgery: results of a prospective survey of 10,811 patients. Br J Anaesth. 2000;84(1):6–10. - PubMed